Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) held today, April 23, 2026. The approvals included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. However, the motions for the extraordinary part of the meeting were not put to a vote because the required quorum was not reached.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected board members, anticipating their valuable contributions. He also thanked Patrick Langlois and Luca Benatti, who stepped down after long service, for their support.
Newron is a biopharmaceutical company dedicated to developing novel therapies for central and peripheral nervous system diseases. Its lead compound, evenamide, is a first-in-class glutamate modulator currently in the global pivotal ENIGMA-TRS Phase III development program for treatment-resistant schizophrenia (TRS) and poorly responding schizophrenia patients. Clinical results have shown significant improvements in efficacy measures and a favorable safety profile. Newron has partnered with EA Pharma for Japan and other Asian territories, and Myung In Pharm for South Korea for evenamide. The company's marketed product, Xadago®/safinamide, is approved in multiple regions for Parkinson's disease, commercialized by partners Zambon, Supernus Pharmaceuticals, and Meiji Seika.
For more information, visit Newron's website.
